REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

May 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-05-14

Reporting Person: STAHL NEIL (EVP Research and Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-25	Common Stock	G	435	$0.0	Disposed	24280	Direct
2021-05-14	Common Stock	M	40000	$179.13	Acquired	64280	Direct
2021-05-14	Common Stock	F	27775	$516.69	Disposed	36505	Direct
2021-05-14	Common Stock	M	12500	$52.03	Acquired	49005	Direct
2021-05-14	Common Stock	F	7204	$516.69	Disposed	41801	Direct
2021-05-17	Common Stock	S	3379	$518.63	Disposed	38422	Direct
2021-05-17	Common Stock	S	10336	$519.47	Disposed	28086	Direct
2021-05-17	Common Stock	S	3806	$520.17	Disposed	24280	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-14	Non-Qualified Stock Option (right to buy)	$52.03	M	12500	Disposed	2021-12-16	Common Stock (12500)	Direct
2021-05-14	Non-Qualified Stock Option (right to buy)	$179.13	M	40000	Disposed	2022-12-14	Common Stock (40000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5787	Indirect
Common Stock	9134	Indirect

Footnotes

F1: Represents volume-weighted average price of sales of 3,379 shares of Company stock on May 17, 2021 at prices ranging from $518.02 to $518.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price.

F2: Represents volume-weighted average price of sales of 10,336 shares of Company stock on May 17, 2021 at prices ranging from $519.00 to $519.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price.

F3: Represents volume-weighted average price of sales of 3,806 shares of Company stock on May 17, 2021 at prices ranging from $520.02 to $520.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price.

F4: The option became exercisable on December 31, 2014, based upon the satisfaction by the Company of certain performance criteria during the period ended December 31, 2014.

F5: The stock option award vested in four equal annual installments, commencing one year after the date of grant.